Compared to non-PRRT2-related PKD, in PRRT2-mutation carriers the age at onset is earlier, the episodes last longer and occur with higher frequency, phenomenology of attacks more frequently combines both dystonia and chorea and lower carbamazepine doses (50–100 mg/day) are effective [23,32,167,168]. The gene discussed is PRRT2; the disease is choreatic disease.